FDA Seeks to Restrict Rucaparib to Second-line Maintenance Therapy in Recurrent Ovarian Cancer

November 18, 2022 11:51 am

by Jason Harris

The FDA has asked Clovis Oncology to limit use of rucaparib (Rubraca) to second-line maintenance therapy for patients with recurrent ovarian cancer harboring BRCA mutations.1

fdaThe company is considering the FDA’s request. If the 2 sides

Read more

FDA Approves Mirvetuximab Soravtansine-gynx for FRα+ Platinum-resistant Ovarian Cancer

November 14, 2022 12:21 pm

By Kristi Rosa

The FDA has granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere) for the treatment of adult patients with folate receptor α (Frα)–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received 1 to 3 prior … Read more

FDA Requests Restriction of Second-line Maintenance Niraparib Indication in Ovarian Cancer

November 14, 2022 11:41 am

by Kristi Rosa

At the request of the FDA, GlaxoSmithKline (GSK) plc will restrict the second-line maintenance indication for niraparib (Zejula) to only the population of patients with recurrent ovarian cancer whose tumors harbor deleterious or suspected deleterious germline BRCA

Read more

Penn Study Illuminates Why Cancers Caused by BRCA Mutations Recur

November 10, 2022 11:36 am

Findings uncover possible drivers of recurrent breast and ovarian cancers among women carrying high-risk genetic mutations, pointing to methods to more effectively treat disease

PHILADELPHIA — Researchers at the University of Pennsylvania’s Basser Center for BRCA at the Abramson Cancer … Read more

Black women less likely to receive guideline-concordant therapy for ovarian cancer

November 9, 2022 11:23 am

by Matthew Shinkle

Black women in the U.S. appeared less likely than white women to receive guideline-concordant treatment for ovarian cancer, according to a study published in Journal of the National Comprehensive Cancer Network.

Even among white women, the … Read more

Restoring the gut biome after antibiotics could lead to better outcomes for ovarian cancer patients

November 8, 2022 11:09 am

by Cleveland Clinic

Reassessing antibiotic dosage and type could improve survival rates in deadliest gynecologic malignancy, Cleveland Clinic research finds

Newswise — CLEVELAND – Antibiotics routinely used in ovarian cancer care indiscriminately kill gut bacteria, leading to faster cancer progression … Read more

Preventing Chemo Brain? Study Identifies Potential Approach for Common Problem

November 2, 2022 4:22 pm

by NCI Staff

A side effect of some cancer treatments commonly referred to as “chemo brain” has received increasing attention from researchers in recent years. Often referred to as cancer-related cognitive impairment, chemo brain can be marked by severe memory … Read more

Ovarian cancer surveillance results in earlier diagnosis for women with faulty BRCA genes who want to defer surgery

November 1, 2022 4:17 pm

by British Medical Journal

Regularly monitoring women with faulty BRCA genes that make them highly susceptible to ovarian cancer results in earlier stage diagnosis in those who want to defer preventive surgery, finds research published online in the Journal of Read more

Anti-cancer drugs, olaparib and adavosertib, work best when given sequentially in patients with advanced tumours driven by DNA damage response mutations: results from Phase Ib STAR clinical trial

October 27, 2022 2:26 pm

Barcelona, Spain: Patients with cancers that are driven by certain mutations occurring in response to DNA damage can be safely treated with two drugs, olparib and adavosertib, if they are given in sequence rather than concurrently.

Presenting results from the … Read more

Melissa Frey, MD, on Disparities in Ovarian Cancer Genetic Testing

October 19, 2022 10:40 am

by Mark L. Fuerst

Most people with a hereditary ovarian cancer syndrome are unaware of their underlying mutation, and the majority have not had genetic testing.

In a recent article in the ASCO Educational Book, Melissa Frey, MD, MS, … Read more

Eligibility Not Responsible for Under Representations in Cancer Clinical Trials

October 18, 2022 10:16 am

by Jessica Nye, PhD

Left image: Eligibility and opportunity for participation in cancer clinical trials was found to be similar across race, level of disadvantage, and residential area. Source: Getty Images

Eligibility was not found to drive disparities in clinical … Read more

Insurance Type Linked With Disparities in the Treatment of Gynecologic Cancer

October 14, 2022 10:36 am

by Jordyn Sava

In the interview with Targeted Oncology, Anna Jo Bodurtha Smith, MD, discusses the effects various insurance types have on the quality of care of patients with gynecologic cancers.Whether a patient with gynecologic cancer has insurance or is … Read more

Mirvetuximab Soravtansine Generates Improvement in PROs Vs Chemotherapy in Advanced Ovarian Cancer

October 13, 2022 2:03 pm

by Chris Ryan

Treatment with mirvetuximab soravtansine elicited a statistically significant benefit vs investigator’s choice of chemotherapy for the OV28 abdominal/gastrointestinal symptom subscale in patients with folate receptor alpha–positive, advanced ovarian cancer.

Treatment with mirvetuximab soravtansine elicited a statistically significant

Read more

Study could help recommend the best treatment for women with early-stage mucinous ovarian cancer

October 12, 2022 1:23 pm

by Emily Henderson, B.Sc.

A global study into mucinous ovarian cancer could help oncologists recommend the best treatment for women who are diagnosed early with the condition.

By looking down a microscope for two different ‘patterns of invasion’ – the … Read more

Identifying the Underlying Causes of Ovarian Cancer

October 6, 2022 1:48 pm

by Cedars-Sinai

New Studies Led by Cedars-Sinai Investigators Help Pinpoint Genetic Risk Factors Tied to Increased Risk of Ovarian Cancer and Suggest How to Better Identify Women Most At Risk

Image on left: Simon Gayther, PhD, professor of Biomedical Sciences, Read more

Elizabeth Swisher, MD, on Predicting Therapy Benefits in Ovarian Cancer

October 5, 2022 4:42 pm

by Mark L. Fuerst

– KELIM score can now be used to look at upfront response, study showed

Tumor primary chemosensitivity testing can help determine if ovarian cancer patients need a boost along with first-line chemotherapy. In the VELIA trial, … Read more

Hannah C. Karpel, MS, Talks Increasing Clinical Trial Accrual in Patients With Gynecologic Malignancies Following NCI Call-to-Action

October 4, 2022 10:04 am

by Ariana Pelosci

A recent study presented at IGCS 2022 looking at clinical trial enrollment found that Black patients experienced the biggest increase in accrual following an NCI call-to-action for more diversity in clinical trials.

A recent single-institution study presented

Read more

First-Line Maintenance Rucaparib Achieves Longer PFS Vs Placebo Across Subgroups in Newly Diagnosed Ovarian Cancer

September 30, 2022 1:15 pm

by Russ Conroy

Results from the phase 3 ATHENA-MONO study suggest that rucaparib could serve as a promising first-line maintenance treatment option in newly diagnosed ovarian cancer.

First-line maintenance rucaparib (Rubraca) yielded higher progression-free survival (PFS) compared with placebo among

Read more

ASCO Addresses PARP Controversy in Guideline Update

September 28, 2022 12:01 pm

— A response to “practice-changing data” in the first- and second-line setting

by Mike Bassett

An updated recommendation from the American Society of Clinical Oncology (ASCO) warns against the routine use of PARP inhibitor monotherapy in the second- or later-line

Read more

Pembrolizumab Plus Bevacizumab and Cyclophosphamide Shows Promising Efficacy, Tolerability in Recurrent Ovarian Cancer

September 26, 2022 9:49 am

by Megan Hollasch

Real-world data from a retrospective study showed that pembrolizumab combined with the anti-VEGF agent bevacizumab plus oral metronomic cyclophosphamide displayed minimal toxicity in a significant number of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal Read more